Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsA. D'Arienzo, Filippo Montemurro, Annarita Verrazzo et al.|EClinicalMedicine|2023Cited by 90
New steps on an old path: Novel estrogen receptor inhibitors in breast cancerMartina Pagliuca, Mario Giuliano, Roberta Scafetta et al.|Critical Reviews in Oncology/Hematology|2022Cited by 23
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|EClinicalMedicine|2025Cited by 7
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysisRoberto Buonaiuto, Michelino De Laurentiis, Aldo Caltavituro et al.|The Breast|2024Cited by 4
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma ArchetypeAldo Caltavituro, Mario Giuliano, Roberto Buonaiuto et al.|Biomedicines|2023Cited by 3